Kornimate/medical-research-clean huggingface dataset:
ocular findings of polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: purpose: this study aimed to compare the ocular surface disease test results, anterior segment parameters, and ocular response analyzer (ora) findings of polycystic ovary syndrome (pcos) patients with those of healthy reproductive age female controls.


Eligibility criteria:
inclusion criteria: * premenopausal with pcos exclusion criteria: * patients with external ocular disease other than dry eye complaints, * use of topical drops that can affect the tear film layer, * contact lens use histories, * those who received hormone therapy for 6 months, * those who have systemic medication or systemic disease that may affect the tear film layer and reproductive physiology, * previous eye surgeries, * smokers and alcohol users, * those having diseases (cushing's syndrome or androgen-secreting tumors) causing similar clinical findings.
treatment of central sleep apnoea in patients with heart failure with nasal high flow therapy (nhft)

Conditions: Central Sleep Apnea; Cheyne-Stokes Respiration

Summary: to investigate whether nhft is an effective treatment for patients with chronic heart failure (chf) and central sleep apnea (csa). this study is a prospective one armed uncontrolled intervention pilot study investigating 4 weeks of nhft at home in 10 patients with chf and csa.

study population: 10 chf patients with a left ventricular injection fraction(lvef)\ 15/hour); with at least 50% of the total number of events having a central character will be included. patients with other diseases that will influence the respiratory system negatively during sleep i.e. chronic obstructive pulmonary disease (copd global initiative of obstructive lung diseases (gold) class 3 and 4), neuromuscular diseases and thorax cage deformities, as well as patients with chf and csa that use another form of treatment for their csa at the time of inclusion, will be excluded. intervention: nhft will be titrated during a first titration night and used at home during the night for 4 weeks consecutively. main study parameters/endpoints: 1. to investigate the effect of nhft with and without oxygen in reducing the apnoea/hypopnoea index during sleep after 4 weeks use nhft. 2. to investigate improvements in oxygen desaturation index, sleep quality and sleepiness, physical condition, left ventricular ejection fraction (lvef), heart beat variability (hrv), n-terminal natriuretic peptide (ntprobnp) after 4 weeks use nhft . 3. physiological condition; work of breathing and respiratory drive and measuring mouth-throat pressure.

Eligibility criteria:
inclusion criteria: 1. moderate to severe csa/csr (ahi\>15), in which csa is defined when at least 50% of the apnoeas are central apnoeas 2. heart failure with reduced ejection fraction, defined as a lvef \< 45% of predicted exclusion criteria: 1. other diseases affecting respiration during sleep (copd gold 3 or 4, neuromuscular disorders, thorax cage deformities) 2. at the moment of the inclusion, the patient does not have a therapy to treat the csa, such as continuous positive airway pressure (cpap), oxygen, bilevel intermittent positive airway pressure (bipap) or acetazolamide.

Keywords: high flow oxygen therapy
comparative effects of heavy slow resistance training and eccentric overload training in runners

Conditions: Sports Physical Therapy

Summary: patellar tendinopathy (pt) also known as jumper's knee, is characterized by multifaceted activity-related pathology causing anterior knee pain and patellar-tendon dysfunction. it most commonly affects athletic activities that involve jumping and running. tendinopathy is most likely to be related to mechanical loading and overuse. athletes suffer from insidious well-localized pain, typically as the athlete starts the activity. conservative treatment is the first line of treatment in tendinopathy, however, there is no consensus regarding the best treatment. in acute conditions, relative rest rather than immobilization is preferred. the most popular non-operative treatment involves eccentric exercise (ee). it is commonly accepted that surgical treatment must be indicated in motivated patients if carefully followed conservative treatment (physical training, injections, eswt) is unsuccessful after 3-6 months. in recent studies, isometric and heavy slow resistance (hsr) exercises have demonstrated potential for pain reduction and functional improvement in patellar tendinopathy. a randomized controlled trial will be conducted at the pakistan sports board (psb) coaching center, lahore. 18 subjects will be randomized into two groups; heavy slow resistance exercises plus eccentric exercises will be given to group a and exercises of 4 sets of 10-20 repetitions will be given. group b will give eccentric exercises in 3 sets of 10-20 repetitions. pre-assessments will be taken through the numeric pain rating scale (nprs) for pain, a goniometer for range of motion, lower extremity function assessment scale to evaluate lower limb functional impairments, and a visa-p scale for patellar dysfunction. assessment will be done at baseline and post 4 weeks of training. data will be analyzed using spss software version 21. the normality of data will be checked, and tests will be applied according to the normality of the data, either parametric or non-parametric tests will be used (within a group or between two groups).

the objective of the study is to compare the effects of heavy slow resistance training and eccentric overload training on pain, range of motion, and lower extremity functions in runners with patellar tendinopathy. .

Eligibility criteria:
inclusion criteria: * anterior knee pain located on the inferior pole of the patella for at least 3 months while practicing sport; * age between 18 and 45 years old; * practicing any kind of sports at least 3 times a week * score less than 80 on the victorian institute of sport assessment-patellar questionnaire (visa-p). exclusion criteria: * knee surgery within the previous 6 months; * chronic joint diseases; * corticosteroid injection in the patellar tendon within the previous 3 months; * anti-inflammatory, analgesic, or antibiotic medications within the previous 48 hours; * any other concomitant treatment for pt

Keywords: exercise heavy slow resistance jumper's knee pain patellar tendinopathy
effects of green propolis extract (epp-af) on inflammation in hemodialysis patients.

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis

Summary: end-stage chronic kidney disease is associated with the condition of chronic inflammation. patients on hemodialysis are known to be predisposed to several factors that predispose to inflammation: dialysis membranes, central venous catheters, oxidative stress, fluid overload, sodium overload, uraemic toxins. propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, and anti-oxidant properties. the aim of this study was to evaluate the impact of brazilian green propolis extract on inflammation in hemodialysis patients.

randomized open-label cross-over trial to investigate impact of brazilian green propolis extract on inflammation in hemodialysis patients.

Eligibility criteria:
inclusion criteria: * age over 18 years; * male or female on hemodialysis for at least 1 month. exclusion criteria: * pregnant woman; * carriers of active neoplasms; * patients undergoing kidney transplantation during the study; * infection during the study; * patients who underwent parathyroidectomy during the study; * patient using immunosuppressive drugs; * allergy to propolis or any of its components;

Keywords: inflammation propolis high-sensitivity c-reactive protein hemodialysis
digital therapy for fatty liver disease

Conditions: Steatohepatitis, Nonalcoholic; Nonalcoholic Fatty Liver

Summary: this study is a randomised controlled trial of the clinical application of the fatty liver data analysis and intervention system (fldas) to compare the effectiveness of traditional lifestyle interventions in patients with fatty liver with digital therapies combining software and hardware devices; to validate the effectiveness of digital therapies in patients with fatty liver; and to evaluate the effectiveness of remote lifestyle (diet and exercise) interventions. researchers conducted a randomised controlled trial to compare the effectiveness of a traditional lifestyle intervention for patients with fatty liver with a remote lifestyle (diet and exercise) intervention combining digital therapy software and hardware devices. when the effectiveness of this programme is validated, it could help clinicians improve the efficiency of lifestyle interventions for patients with fatty liver and address the growing need for primary care for patients with fatty liver as an innovative approach to disease intervention.


Eligibility criteria:
inclusion criteria: * nafld patient (cap value \>248 (db/m)) * age 18-65 years old, 24kg/m2 ≤ bmi ≤ 35kg/m2 * must be able to use smartphone exclusion criteria: * inherited metabolic or autoimmune liver disease * drug/toxic/alcoholic/biliary liver injury, cirrhosis or any end-stage liver disease * hepatic or extrahepatic malignant tumours * pregnant and lactating women * patients considered ineligible by the investigator's clinical judgment
assessing the treatment effect in metabolic syndrome without perceptible diabetes (attempt)

Conditions: Metabolic Syndrome

Summary: the objective of this protocol is to improve awareness, treatment, and control of metabolic syndrome, within primary prevention of cardiovascular disease, by implementing guidelines, after training of the participating physicians.

physicians from 20 hospitals or health centres (primary and secondary health care settings) were trained to implement guidelines in treating metabolic syndrome. there will be a baseline recording of patients with metabolic syndrome and then physicians will have to complete a one page form (by ticking pre-specified boxes) about the baseline status of the patients and will have to report the measures they took to improve awareness, treatment, and effective control of the metabolic syndrome. with 6 month intervals (up to 36 months at study completion) physicians will have to complete the same form. previous training of physicians and the fact that they will have to report their success in treating metabolic syndrome will hopefully contribute to an increase in number of patients with the syndrome at treatment targets, and will minimise the target organ damage (i.e cardiovascular disease). the estimated 10-year reduction in coronary heart disease risk will be evaluated by a comparison of this risk (as evaluated by a risk engine, i.e. procam) at the 6th month and at study completion with that of baseline.

Eligibility criteria:
inclusion criteria: * metabolic syndrome (ncep atp iii definition modified to aha/nhlbi definition) exclusion criteria: * pregnancy * lactation * malignancies with small life expectancy * unwillingness to participate

Keywords: metabolic syndrome obesity hyperlipidemia high blood pressure diabetes
oral sodium fusidate (cem-102) for the treatment of staphylococcal bone or joint infections

Conditions: Refractory Bone or Joint Infections

Summary: to evaluate the safety and effectiveness of oral sodium fusidate (cem-102) as chronic antibiotic for the treatment of bone or joint infections.

prospective, open-label, non-randomized, single-arm trial to evaluate the safety and effectiveness of cem-102 for chronic antibiotic suppressive therapy of bone or joint infections. subjects enrolling in this study must have a refractory staphylococcal bone or joint infection that requires suppressive antibiotic therapy (e.g. having an infection that cannot be managed by complete removal of the infected bone or foreign material, a refractory infection not responding to previous treatment, or not being a candidate for long-term intravenous antibiotic therapy).

Eligibility criteria:
inclusion criteria: * adolescents between 12 and 18 years must weigh \>60 kg * bone or joint infection due to an inclusionary pathogen demonstrated from a culture from samples obtained within 6 weeks prior to enrollment * not a candidate, as determined by the investigator, for suitable alternative therapy * after completion of 1-2 weeks of the companion antibiotic, must be a suitable candidate for cem-102 monotherapy for chronic treatment exclusion criteria: * requires concomitant treatment with oatp1b1 and oatp1b3 substrates, in particular, statins (hmg-coa reductase inhibitors) * known severe renal impairment, as indicated by estimated crcl \<30 ml/min (by cockcroft-gault calculation) * evidence of significant liver disease: alt \>3 × uln or direct bilirubin \>uln; known cirrhosis with decompensation (i.e. child-pugh class b or c disease)

Keywords: fusidic acid prosthetic joint infections bone infections osteomyelitis
inetetamab combined with pyrotinib and vinorelbine as first-line to third-line treatment for her2-positive metastatic breast cancer

Conditions: Breast Neoplasms

Summary: this is a real world study to evaluate the efficacy and safety of inetetamb combined with pyrotinib and vinorelbine as first-line to third-line treatment after trastuzumab progression in her2-positive metastatic breast cancer.

her2-positive breast cancers account for 15%-20% of all breast cancers. despite trastuzumab has significantly improved the survival of patients with her2-positivie metastatic breast cancer as the first-line standard treatment, the selection of drugs after trastuzumab treatment failure remains difficulty and challenge. inetetamab, a new antibody to optimize the adcc effect, has shown great effectiveness in treating her2-positive metastatic breast cancer, but therapies subsequent to trastuzumab progression are still controversial. pyrotinib, another second-line her2 targeted drug, is a typical representative of tki drugs, which not only has a strong her2 antagonistic effect but also can synergize with monoclonal antibodies to amplify the adcc effect. here, investigators studied the efficacy and safety of inetetamb combined with pyrotinib and vinorelbine as first-line to third-line treatment after trastuzumab progression, so as to provide new ideas for the treatment of patients with her2-positive metastatic breast cancer.

Eligibility criteria:
inclusion criteria: 1. female and 18-80 years old; 2. the patient was diagnosed as her2-positive breast cancer by histopathology (her2 positive (ihc +++ or ihc++ but fish/cish+ )); 3. all patients have previously received ≤ 2 lines chemotherapy for metastatic breast cancer; 4. patients received inetetamab combined with pyrotinib and vinorelbine after trastuzumab failure; 5. according to recist 1.1, patients with at least one target lesion or simple bone metastasis can be evaluated; 6. ecog score of physical status was less than 2, and the expected survival time was not less than 3 months; 7. complete and traceable medical data. exclusion criteria: 1. incomplete medical data; 2. the investigator believes that the patient is not suitable to enter this study.
is there any correlation between respiratory variation ratios of internal jugular vein and inferior vena cava?

Conditions: Critically Ill

Summary: intravascular volume assesment is important for the management of the patients in the intensive care unit. respiratory variation ratio of the inferior vena cava (ivc) can be determined by ultrasonography (usg) and is a useful tool for hemodynamic evaluation of the patient. aim of this study is to search for correlation between respiratory variation ratios of the internal jugular vein (ijv) and the ivc before and after passive leg raise. another aim of this study is to search for variability between ultrasonographic measurements of different doctors.

the investigators measure the internal jugular vein (ijv) diameter in the short axis by using the linear probe (12-5 mhz) and m-mode of the ultrasound device in the junction of cricothyroid membrane level and midclavicular line. the inferior vena cava (ivc) is visualized in the subxiphoid long axis by using the convex probe (5-1 mhz). diameter of the ivc is measured 2 cm caudally to the junction of the hepatic vein in m-mode. all measurements are done separately by 3 different doctors; one senior anesthesiology resident, one anesthesiology and critical care medicine fellow and one professor in anesthesiology and critical care. the first measurements of the ivc and the ijv are done in the supine position and the second ones are done after passive leg raise. passive leg raise is done for 1 minute in the first group and for 3 minutes in the second group. then distensibility (maximum diameter - minimum diameter / minimum diameter) and collapsibility (maximum diameter - minimum diameter / maximum diameter) indices are calculated. no fluid therapy or medication are given to the patients according to these measurements. oxygen saturation, hearth rate and blood pressure levels are recorded before and after the measurements. the investigators also record age, gender, weight, height, body mass index, causes of admission, comorbidities, ventilator settings, vasoactive and diuretic medications, fluid intake and output volumes, acute physiology and chronic health evaluation ii (apache ii) and sepsis-related organ failure assessment (sofa) scores in the day of admission, acute physiology score (aps) and sofa scores in the day of measurement and length of stay in the intensive care unit. patients with infection or surgical sutures in the site of measurement areas, intraabdominal hypertension, severe aortic regurgitation or lower extremity amputation history are excluded from the study.

Eligibility criteria:
inclusion criteria: * mechanically ventilated * over 18 years of age exclusion criteria: * infection in the site of measurement areas * surgical sutures in the site of measurement areas * intraabdominal hypertension * severe aortic regurgitation * lower extremity amputation

Keywords: positive pressure ventilation fluid responsiveness passive leg raise inferior vena cava internal jugular vein interobserver variability ultrasound
effects for oral mucositis care during chemoradiotherapy in cancer patients: evaluation of the bee products

Conditions: Oral Mucositis

Summary: oral mucositis is common among cancer patients receiving radiotherapy and chemotherapy. 80-90% of the patients are suffering from the mucositis pain; poor nutrition and even treatment discontinued. some self-paid medications like glutamine has been used to prevent mucositis before and during radiotherapy/chemotherapy. randomized controlled trials have shown that honey and propolis may be used for the management of mucositis. honey demonstrates the most significant antibacterial effects; the green propolis has also been proved to comprise antibacterial, anti-inflammatory, and antioxidant effects. bee products have been concerned as potential sources of natural antioxidants such as flavonoids, phenolic acids, and terpenoids. this study plan to conduct an rct comparing the effectiveness of honey, honey and green propolis, and usual care in mucositis of cancer patients.

outcome measures 1. questionnaire collection: oral mucositis grade, pain scale, fatigue scale, dry mouth, nutritional status and quality of life scale. 2. wearing the smart bracelet: the smart bracelet will automatically detect heart rate variability, heartbeat, sleep and activity status. 3. saliva sample collection: test the concentration of il-1, il-6, il-10 and tnf in saliva. 4. stool and oral flora collection: test stool and oral flora microbiota.

Eligibility criteria:
inclusion criteria: 1. diagnosed with a head and neck tumor. 2. receive chemotherapy or radiotherapy. 3. conscious clear and willing to participate in the research. 4. can communicate in mandarin or taiwanese. exclusion criteria: diabetes, arrhythmia, artificial heart rhythm device, allergic to bee products or alcohol.

Keywords: oral mucositis
long-term cancer risk in the randomised oslo diet and antismoking study

Conditions: Cancer; Gastrointestinal Cancer; Lung Cancer; Urinary Tract Cancer; Prostate Cancer

Summary: this study examines the effect of a five-year multifactorial lifestyle intervention in the oslo diet and antismoking study on long-term cancer risk. in 1972-1973, 1232 men with high cardiovascular risk profile were randomised to intervention including cholesterol lowering diet, weight loss and antismoking advice, or control (1:1). this study examines the effect of the intervention on 43-year cancer incidence and mortality.

the oslo diet and antismoking study showed that a 5-year lifestyle intervention reduced the long-term risk of coronary events and mortality. the lifestyle risk factors for cancer are partly similar to those for coronary heart disease, e.g. smoking, high body weight, unfavourable diet. the investigators therefore expect that the intervention has an effect on cancer risk in the long term. in this follow-up study, the investigators analyse the association between the intervention, and cancer incidence and mortality drawn from the cancer registry of norway and the norwegian cause of death registry from the time of randomisation in 1972/3 until the end of 2015.

Eligibility criteria:
inclusion criteria: * participated in screening of coronary risk factors, into which all men born in 1923-1932 and living in oslo were invited in 1972-1973 * being in the upper quartile of a coronary risk score based on blood pressure, serum total cholesterol concentration and cigarette smoking exclusion criteria: * serum total cholesterol level above 9.0 mmol per liter * having a healthy diet, based on a short dietary history * self-reported cardiovascular disease or diabetes * previous history of cancer

Keywords: cancer risk randomised trial intervention smoking cessation dietary intervention weight loss